DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Delcath Systems, Inc. (DCTH) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | D- (1.1) | B+ (3.8) | B+ (3.7) | B+ (3.8) | C+ (2.6) | B- (3.0) |
| 2026-11-04 | D (1.5) | B- (3.0) | B+ (3.7) | A- (4.0) | C+ (2.7) | B- (3.0) |
| 2026-10-28 | D (1.5) | B- (3.0) | B+ (3.7) | A- (4.1) | C+ (2.7) | B- (3.0) |
| 2026-10-21 | D (1.5) | B- (3.0) | B+ (3.7) | B+ (3.8) | C+ (2.6) | B- (2.9) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe